Magaldrate
![]() | |
| Gene therapy | |
|---|---|
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a682683 |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code |
|
| Physiological data | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Negligible |
| Metabolism | Nil |
| Excretion | Fecal and renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem Template:Abbreviation | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | AlMg2(OH)7·H2O |
| Molar mass | 212.66 g/mol |
| |
| (verify) | |
|
WikiDoc Resources for Magaldrate |
|
Articles |
|---|
|
Most recent articles on Magaldrate |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Magaldrate at Clinical Trials.gov Clinical Trials on Magaldrate at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Magaldrate
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Magaldrate Discussion groups on Magaldrate Patient Handouts on Magaldrate Directions to Hospitals Treating Magaldrate Risk calculators and risk factors for Magaldrate
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Magaldrate |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.
Available forms
Magaldrate is available in the form of oral suspension or tablets.
Pharmacology
Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly in gastric acid to Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[1]
Interactions and adverse reactions
Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
Brand names
The drug is sold with the following brand names: Digecid Plus (Beximco Pharma, Bangladesh), Marlox Plus (Incepta pharma Bangladesh), Gastid (SK+F, Bangladesh), Novelta (Bangladesh), Gadral (Italy); Magaltop (Italy); Magralibi (Italy); Mylanta (Australia); Riopan (Argentina, Austria, Brazil, Egypt, Germany, Italy, Mexico, Belgium, Switzerland, Greece).
References
- ↑ Laurence L., Brunton. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.
- Articles with short description
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Infobox-drug molecular-weight unexpected-character
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes which contain changes to watched fields
- Drug
- Magnesium compounds
